Millennium Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Millennium Management LLC bought a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 30,305 shares of the company's stock, valued at approximately $588,000. Millennium Management LLC owned about 0.09% of Oruka Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ORKA. Janus Henderson Group PLC boosted its holdings in shares of Oruka Therapeutics by 259.7% in the 4th quarter. Janus Henderson Group PLC now owns 849,410 shares of the company's stock valued at $16,415,000 after buying an additional 613,294 shares during the last quarter. Jefferies Financial Group Inc. acquired a new stake in Oruka Therapeutics during the 4th quarter valued at $6,787,000. Fairmount Funds Management LLC lifted its holdings in Oruka Therapeutics by 5.0% during the 4th quarter. Fairmount Funds Management LLC now owns 3,371,922 shares of the company's stock valued at $65,382,000 after purchasing an additional 160,000 shares during the last quarter. Braidwell LP lifted its holdings in Oruka Therapeutics by 122.5% during the 4th quarter. Braidwell LP now owns 1,147,676 shares of the company's stock valued at $22,253,000 after purchasing an additional 631,950 shares during the last quarter. Finally, Blackstone Inc. acquired a new stake in shares of Oruka Therapeutics during the fourth quarter worth $4,657,000. Institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Stock Performance

ORKA opened at $12.58 on Friday. The firm has a market cap of $471.01 million, a P/E ratio of -2.01 and a beta of -0.38. The firm has a 50-day moving average of $9.82 and a 200 day moving average of $13.31. Oruka Therapeutics, Inc. has a fifty-two week low of $5.49 and a fifty-two week high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. Equities research analysts predict that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Wall Street Zen upgraded Oruka Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Wedbush reiterated an "outperform" rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research report on Thursday, May 15th. Finally, BTIG Research started coverage on Oruka Therapeutics in a research report on Thursday, May 22nd. They issued a "buy" rating on the stock. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Oruka Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $40.38.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.